SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $11,136,250,185 |
| Positions | 26 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| UNITED THERAPEUTICS CORP | UTHR | Common | $1,505,082,912 | 2,777,777 |
| ASCENDIS PHARMA | ASND | ORDINARY SHARES | $1,363,235,526 | 5,111,111 |
| KRYSTAL BIOTECH INC | KRYS | Common | $1,073,713,003 | 2,888,888 |
| MADRIGAL PHARMACEUTICALS INC | MDGL | Common | $984,408,154 | 1,833,333 |
| ARGENX SE | ARGX | Sponsored ADR | $927,770,000 | 1,000,000 |
| ARROWHEAD PHARMACEUTICALS INC | ARWR | Common | $925,591,288 | 11,355,555 |
| KYMERA THERAPEUTICS INC | KYMR | Common | $857,129,238 | 7,474,747 |
| REVOLUTION MEDICINES INC | RVMD | Common | $430,182,160 | 2,297,000 |
| CYTOKINETICS INC | CYTK | Common | $425,949,915 | 4,999,999 |
| CELCUITY INC | CELC | Common | $355,708,000 | 3,400,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.